Are There More Optimal Approaches to Managing Pricing and Reimbursement of Multi-Indication Medicines to Better Facilitate Patient Access?

ISSUE:

Medicines with multiple indications are increasingly common and can bring value through added treatment options for patients and potential efficiency gains due to a well understood mechanism of action and safety profile. At the same time, the value of each indication can vary, so a single price cannot capture the value of individual indications. European countries have different ways of managing multi-indication medicines, but in practice lengthy negotiations and price erosion are still common, which can delay or restrict patient access and launch sequencing. Indication-based pricing applies distinct prices for different indications and has been suggested as a solution, however, it is difficult to implement, and most countries adopted a blended approach.

There is a need to explore solutions to manage the pricing and reimbursement (P&R) of multi-indication medicines in a more optimal way for all stakeholders. This session therefore brings together different stakeholder perspectives to discuss potential solutions for the management of multi-indication medicines.

OVERVIEW:

An overview of multi-indication medicines based on a scoping literature review will be presented, including key P&R challenges and proposed solutions (10 minutes, moderator). Challenges and solutions will first be discussed from a broad, international perspective, highlighting the views of different stakeholders (13 minutes, Amanda Cole). They will then be examined from a country-specific perspective (Italy) to explore what the solutions could solve and what is feasible in practice (13 minutes, Claudio Jommi). Finally, the challenges and solutions will be commented on from the industry perspective (13 minutes, Julien Patris).

The audience will then be invited to comment and ask questions to the panellists. The intention of the discussion will be to explore what potential solutions for multi-indication medicines are effective and feasible, and can benefit all stakeholders (11 minutes). This panel session may benefit payers, policy makers, patient organisations and manufacturers.